Breaking News

Bavarian Nordic Receives $120M HHS Contract for Smallpox/Mpox Vax

Will support manufacturing of new bulk vaccine to partly replenish the inventory used for the mpox outbreak in 2022.

Bavarian Nordic reported that the U.S. Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services (HHS), has placed a new order valued at $120 million, primarily covering the manufacturing of new bulk product for the company’s smallpox/mpox vaccine. The bulk product, representing $96 million of the contract value, will be manufactured, and invoiced in 2023 and will only ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters